![Two men, seated indoors around a table, engaged in a conversation and playing chess Two men, seated indoors around a table, engaged in a conversation and playing chess](https://www.saludhable.novartis.com/sites/novartis_com/files/styles/cards_1_3/public/2023-11/young-and-senior-men-playing-chess-and-laughing.jpg.webp?itok=qlEDLubb)
Discover our medicines
Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
![A female research scientist in a lab looking at a sample A female research scientist in a lab looking at a sample](https://www.saludhable.novartis.com/sites/novartis_com/files/styles/cards_1_3/public/2023-11/portrait-research-scientist-cambridge.jpg.webp?itok=XGxCz1ar)
Explore our science
Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
![Group of warm clothed women, seated outside, smiling and laughing Group of warm clothed women, seated outside, smiling and laughing](https://www.saludhable.novartis.com/sites/novartis_com/files/styles/cards_1_3/public/2023-11/group-of-warm-clothed-people-smilling-and-laughing.jpg.webp?itok=wVBQo2cD)
Learn about our impact
Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective.
![Two scientists in a lab testing samples. Two scientists in a lab testing samples.](https://www.saludhable.novartis.com/sites/novartis_com/files/styles/cta_image/public/2024-05/two-scientists-in-lab-testing-sample.jpg.webp?itok=dKDEXpI8)
A legacy of blood cancer innovation
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
Latest news
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
The burden of IgAN
IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients.
![Shanelle Gabriel spending time with her father in New York Shanelle Gabriel spending time with her father in New York](https://www.saludhable.novartis.com/sites/novartis_com/files/styles/cta_image/public/2024-01/shanelle-gabriel-sitting-on-bench-with-her-father-new-york.jpg.webp?itok=kGsAkDwD)
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.